FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

11 letters match. Newest first.

  1. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium
  2. 24HrDoc, Inc. dba 24HrDoc

    FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.

    Medium
  3. FWD Care, Inc. dba FWD

    FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.

    Medium
  4. Aytu Biopharma

    FDA says Aytu Biopharma’s sponsored links for ADHD drug Cotempla XR-ODT are false or misleading and misbrand it.

    High risk
  5. Aytu Biopharma

    FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.

    High risk
  6. Hello Cake, Inc. dba Hello Cake

    FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.

    Medium
  7. Alora Pharmaceuticals

    FDA says Alora's paid search ads for RELEXXII ADHD drug are false or misleading because they omit risk information.

    Low
  8. Curex

    FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

    High risk
  9. Eli Lilly and Company

    FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.

    High risk
  10. Eli Lilly and Company

    FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

    Low
  11. AstraZeneca Pharmaceuticals LP

    FDA says AstraZeneca's Breztri sales aid made false or misleading efficacy claims, making the COPD drug misbranded.

    Low